Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines

Brocato, Rebecca L.; Kwilas, Steven A.; Josleyn, Matthew; Long, Simon Y.; Zeng, Xiankun; Perley, Casey C.; Somerville, Brandon; Cohen, Melanie; Hooper, Jay W.

doi:10.1016/j.vaccine.2021.01.002

Cited by 8 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA vaccines have several advantages, including stability (minimal cold-chain requirements), safety, and increased immunogenicity with administration by needle-free delivery devices [ 4 , 38 , 39 , 40 , 41 ]. However, traditional pDNA manufacture is a major bottleneck [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nucleic acid-based vaccines, more specifically mRNA-based vaccines for the COVID-19 pandemic, have recently gained notoriety. Strategies for overcoming the technical hurdles related to nucleic acid-based vaccines (i.e., low immunogenicity) are being developed with advances in formulation and more effective vaccine delivery systems [ 1 , 2 , 3 , 4 , 5 , 6 ]. Medical countermeasures, including vaccines and therapeutics, are proving imperative for ending the pandemic, warranting the continual evaluation of COVID-19 vaccine approaches.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

et al. 2022

Self Cite

View full text Add to dashboard Cite

To combat the COVID-19 pandemic, an assortment of vaccines has been developed. Nucleic acid vaccines have the advantage of rapid production, as they only require a viral antigen sequence and can readily be modified to detected viral mutations. DoggyboneÔ DNA vaccines targeting the spike protein of SARS-CoV-2 have been generated and compared with a traditionally manufactured, bacterially derived plasmid DNA vaccine that utilizes the same spike sequence. Administered to Syrian hamsters by jet injection at two dose levels, the immunogenicity of both DNA vaccines was compared following two vaccinations. Immunized hamsters were then immunosuppressed and exposed to SARS-CoV-2. Significant differences in body weight were observed during acute infection, and lungs collected at the time of euthanasia had significantly reduced viral RNA, infectious virus, and pathology compared with irrelevant DNA-vaccinated controls. Moreover, immune serum from vaccinated animals was capable of neutralizing SARS-CoV-2 variants of interest and importance in vitro. These data demonstrate the efficacy of a synthetic DNA vaccine approach to protect hamsters from SARS-CoV-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hooper et al, at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), have used NFIS to administer DNA vaccines against various viral infections. This group assessed hantavirus DNA vaccines in a Syrian hamster model and found enhanced immunogenicity, increased local antigen expression in tissues, and less injection site pathology in Tropis NFIS groups compared to PMED and NS delivery ( Table 1 ) [ 79 ]. Although the Tropis system is normally used to deliver ID in larger animals and humans, the group developed a method to deliver IM and SC injections with the device in the smaller hamster model.…”

Section: Comparison Of Nfis To Ep and Pmed Vaccine Deliverymentioning

confidence: 99%

Improved DNA Vaccine Delivery with Needle-Free Injection Systems

et al. 2023

Self Cite

View full text Add to dashboard Cite

DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability. However, a major drawback of candidate DNA vaccines delivered by needle and syringe is the poor immunogenicity associated with inefficient cellular uptake of the DNA. This uptake is essential because the target vaccine antigen is produced within cells and then presented to the immune system. Multiple techniques have been employed to boost the immunogenicity and protective efficacy of DNA vaccines, including physical delivery methods, molecular and traditional adjuvants, and genetic sequence enhancements. Needle-free injection systems (NFIS) are an attractive alternative due to the induction of potent immunogenicity, enhanced protective efficacy, and elimination of needles. These advantages led to a milestone achievement in the field with the approval for Restricted Use in Emergency Situation of a DNA vaccine against COVID-19, delivered exclusively with NFIS. In this review, we discuss physical delivery methods for DNA vaccines with an emphasis on commercially available NFIS and their resulting safety, immunogenic effectiveness, and protective efficacy. As is discussed, prophylactic DNA vaccines delivered by NFIS tend to induce non-inferior immunogenicity to electroporation and enhanced responses compared to needle and syringe.

show abstract

“…Both these problems can be overcome by delivering the vaccine through the use of devices like mucosal injections, gene guns, electroporation techniques, pressure needle-free injections [ 75 , 76 ]. Injecting through gene guns or Pharmajet devices like Tropis and Stratis directly results in the transfection of skin or muscle cells [ 77 ]. Using the electroporation technique, pores are formed in the cells on the application of an electric field which is temporary for ease of transfection of the DNA plasmid in cells [ 78 ].…”

Section: Dna Vaccinesmentioning

confidence: 99%

DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

Chavda

Pandya

Apostolopoulos

2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Coronavirus outbreak 2019 (COVID-19) has affected all the corners of the globe and created chaos to human life. In order to put some control on the pandemic, vaccines are urgently required that are safe, cost effective, easy to produce, and most importantly induce appropriate immune responses and protection against viral infection. DNA vaccines possess all these features and are promising candidates for providing protection against SARS-CoV-2. Area covered: Current understanding and advances in DNA vaccines toward COVID-19, especially those under various stages of clinical trials. Expert opinion: Through DNA vaccines, host cells are momentarily transformed into factories that produce proteins of the SARS-CoV-2. The host immune system detects these proteins to develop antibodies that neutralize and prevent the infection. This vaccine platform has additional benefits compared to traditional vaccination strategies like strong cellular immune response, higher safety margin, a simple production process as per cGMP norms, lack of any infectious agent, and a robust platform for large-scale production.

show abstract

Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines

Cited by 8 publications

References 29 publications

SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

Improved DNA Vaccine Delivery with Needle-Free Injection Systems

DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

Contact Info

Product

Resources

About